TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33338829

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1431
Study: 32499064

Group type: EXPERIMENTAL
Intervention: rVSVΔG‐ZEBOV‐GP vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35770659

Group type: EXPERIMENTAL
Intervention: Self-action observation group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Action observation group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Action practice group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-action observation group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 34030873

Group type: EXPERIMENTAL
Intervention: Perioperative Low-Dose Dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33089290

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gargle combined with mechanical debridement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mechanical debridement (Control)
Number of subjects: 100
Study: 36197699

Group type: COMPARATOR
Intervention: Standard postoperative care (group A)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Early clean intermittent catheterization (CIC) within the first postoperative month (group B)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard postoperative care (group A) at 9 months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Early clean intermittent catheterization (CIC) at 9 months (group B)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups at 3, 6, and 9 months follow-up
Number of subjects: 47
Study: 34997635

Group type: EXPERIMENTAL
Intervention: UNI-PAHNP (Pender's health promotion model‐based Physical Activity and Healthy Nutrition Program)
Number of subjects: 110
Study: 32193269

Group type: EXPERIMENTAL
Intervention: Hybrid CBT
Number of subjects: 25

Group type: COMPARATOR
Intervention: self-help control treatment
Number of subjects: 25
Study: 32745170

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: E6/E7 mRNA
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: p16/ki67
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: Immediate referral
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: Overall referral
Number of subjects: 3147

Group type: COMPARATOR
Intervention: 1-year retesting vs immediate colposcopy
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: E6/E7 mRNA negative women
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: p16/ki67 negative women
Number of subjects: 3147
Study: 32560735

Group type: EXPERIMENTAL
Intervention: Continuing education program for over 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: General information about the correct use of complex dosage forms (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing education program
Number of subjects: 0
Study: 36170036

Group type: EXPERIMENTAL
Intervention: TCFA-positive lesions
Number of subjects: 390

Group type: COMPARATOR
Intervention: TCFA-negative lesions
Number of subjects: 390
Study: 33183107

Group type: EXPERIMENTAL
Intervention: Expert-based criteria for reduction
Number of subjects: 80

Group type: COMPARATOR
Intervention: No expert-based criteria for reduction
Number of subjects: 80
Study: 34450619

Group type: EXPERIMENTAL
Intervention: Molnupiravir 300 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Molnupiravir 600 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Molnupiravir 800 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (standard-of-care)
Number of subjects: 18
Study: 32702335

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 6 months
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 33557706

Group type: EXPERIMENTAL
Intervention: Liars (participants who exaggerated the number of stolen items)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liars (participants who fabricated additional stolen items)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Truth-tellers (participants who reported accurately)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Believability feedback (believable vs. not believable)
Number of subjects: 0
Study: 34979421

Group type: EXPERIMENTAL
Intervention: TXT-CBT
Number of subjects: 50

Group type: COMPARATOR
Intervention: INFO
Number of subjects: 50
Study: 33143327

Group type: EXPERIMENTAL
Intervention: Forest video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urban video control
Number of subjects: 0
Study: 34746976

Group type: EXPERIMENTAL
Intervention: Therapist-assisted internet-delivered cognitive behaviour therapy program
Number of subjects: 13
Study: 32838628

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: White Noise
Number of subjects: 9

Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 9
Study: 32219761

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid arm, receiving two 330 mg omega-3 fatty acid capsules daily and placebo (for vitamin D3) weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D arm, receiving a 50,000 IU vitamin D3 soft gel weekly and two placebos (for omega-3 fatty acids) daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-supplementation arm, receiving a 50,000 IU vitamin D3 soft gel weekly and two 330 mg omega-3 fatty acids capsules daily for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls, receiving placebos
Number of subjects: 0
Study: 35715803

Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine (two formulations: aluminum Alhydrogel and CAF01)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control vaccine (Verorab)
Number of subjects: 50
Study: 33183970

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year
Number of subjects: 2840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2840
Study: 35178136

Group type: EXPERIMENTAL
Intervention: Physiotherapy group (PT) received ELF EMF and LED therapy in addition to Paracetamol and NSAID-ibuprofen.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG) received Paracetamol and NSAID-ibuprofen only.
Number of subjects: 32
Study: 34162641

Group type: EXPERIMENTAL
Intervention: Internet-assisted cognitive behavioural therapy (ICBT) with telephone coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 0
Study: 32108355

Group type: EXPERIMENTAL
Intervention: rhIGF-1 therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (glucocorticoid therapy only)
Number of subjects: 17
Study: 36294115

Group type: EXPERIMENTAL
Intervention: Cha‐cha dance training (CTG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CONG)
Number of subjects: 40
Study: 32865325

Group type: EXPERIMENTAL
Intervention: CAD/CAM NiTi retainer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multi‐stranded stainless steel retainer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single‐stranded nickel‐free titanium retainer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vacuum‐formed removable retainer
Number of subjects: 60
Study: 34401935

Group type: EXPERIMENTAL
Intervention: Closed suction drain (group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No closed suction drain (group B)
Number of subjects: 84
Study: 34445035

Group type: EXPERIMENTAL
Intervention: 3 g·day−1 NZBC extract
Number of subjects: 27
Study: 36446063

Group type: EXPERIMENTAL
Intervention: Health education intervention for COVID-19 prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33744041

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: All meals
Number of subjects: 18
Study: 33346375

Group type: EXPERIMENTAL
Intervention: Olmesartan/rosuvastatin fixed-dose combination (FDC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual regimen (separate angiotensin receptor blockers and statins)
Number of subjects: 150
Study: 35978350

Group type: EXPERIMENTAL
Intervention: Dengyinnaotong Capsule plus routine basic treatment
Number of subjects: 270

Group type: COMPARATOR
Intervention: Routine basic treatment
Number of subjects: 270
Study: 33947825

Group type: EXPERIMENTAL
Intervention: Graston technique plus exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise program only
Number of subjects: 60
Study: 32249446

Group type: EXPERIMENTAL
Intervention: Periodontal regeneration (PR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tooth extraction and replacement (TER)
Number of subjects: 50
Study: 35235823

Group type: EXPERIMENTAL
Intervention: CDS format - text
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: CDS format - text table
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: CDS format - text graphs
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: CDS format - tailored to subject's graph literacy score
Number of subjects: 220
Study: 34376218

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: No beta-blocker therapy (Control)
Number of subjects: 192
Study: 32157334

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 1360
Study: 36267013

Group type: EXPERIMENTAL
Intervention: Cheonwangbosimdan
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 34531203

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 101

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 101
Study: 33167735

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus trastuzumab and chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 0
Study: 34339669

Group type: EXPERIMENTAL
Intervention: Patient‐controlled analgesia with ropivacaine CRIB
Number of subjects: 66

Group type: COMPARATOR
Intervention: Patient‐controlled intravenous analgesia with sufentanil
Number of subjects: 66
Study: 34249145

Group type: EXPERIMENTAL
Intervention: Sufentanil + Lidocaine (S + L)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sufentanil (S)
Number of subjects: 130
Study: 33216275

Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Number of subjects: 94
Study: 35777735

Group type: EXPERIMENTAL
Intervention: Bupivacaine + Ketamine (BK group)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Bupivacaine + Dexmedetomidine (BD group)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Bupivacaine only (B group)
Number of subjects: 159
Study: 34155966

Group type: EXPERIMENTAL
Intervention: Cobalt sulfate at 0.11 mg Co/kg dry matter (DM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Folic acid at 7.2 mg/kg DM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cobalt sulfate at 0.11 mg Co/kg DM
Number of subjects: 40
Study: 35999257

Group type: EXPERIMENTAL
Intervention: NewU (uniform with a new applied fabric treatment)
Number of subjects: 8

Group type: COMPARATOR
Intervention: CurrU (current Army uniform)
Number of subjects: 8
Study: 33462831

Group type: EXPERIMENTAL
Intervention: 200 mg pembrolizumab every 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized dose comparison studies (KN001 B2 and D)
Number of subjects: 0
Study: 33119623

Group type: EXPERIMENTAL
Intervention: Management decisions based on clinical vignettes for appendicitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management decisions based on clinical vignettes for pharyngitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GP's estimated probability of disease for pharyngitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GP's estimated probability of disease for appendicitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correct estimation of probability of disease by GPs for appendicitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correct estimation of probability of disease by GPs for pharyngitis
Number of subjects: 0
Study: 34836880

Group type: EXPERIMENTAL
Intervention: 4-week stepwise return-to-PA protocol at 72 hours post concussion
Number of subjects: 456

Group type: COMPARATOR
Intervention: Resting until asymptomatic
Number of subjects: 456
Study: 35641211

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Ponatinib 45/15 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Ponatinib (general)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Ponatinib (readjudication)
Number of subjects: 261
Study: 33599689

Group type: EXPERIMENTAL
Intervention: Genetically determined tuberculosis susceptibility
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: T‐SPOT.TB positivity
Number of subjects: 999

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 999
Study: 32716706

Group type: COMPARATOR
Intervention: On-time denosumab dosing (within 4 weeks after the recommended date)
Number of subjects: 2594

Group type: EXPERIMENTAL
Intervention: Short delay denosumab dosing (delay by 4 to 16 weeks)
Number of subjects: 2594

Group type: EXPERIMENTAL
Intervention: Long delay denosumab dosing (delay by more than 16 weeks)
Number of subjects: 2594
Study: 35456180

Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 34749668

Group type: EXPERIMENTAL
Intervention: Higher ALA (α-linolenic acid) levels
Number of subjects: 113937

Group type: EXPERIMENTAL
Intervention: DPA (docosapentaenoic acid)
Number of subjects: 113937

Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid)
Number of subjects: 113937

Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid)
Number of subjects: 113937
Study: 36202666

Group type: EXPERIMENTAL
Intervention: THAA group
Number of subjects: 139

Group type: COMPARATOR
Intervention: non-THAA group
Number of subjects: 139
Study: 33657983

Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control
Number of subjects: 484
Study: 32444306

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 114
Study: 35318777

Group type: EXPERIMENTAL
Intervention: Colonic gas filling (720 mL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 16
Study: 32706285

Group type: EXPERIMENTAL
Intervention: Experimental bath wipes containing silver
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard bath wipes containing soap
Number of subjects: 127
Study: 34427115

Group type: EXPERIMENTAL
Intervention: Dostarlimab (Jemperli), administered intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dostarlimab (Jemperli)
Number of subjects: 0
Study: 36328655

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study: 36497688

Group type: EXPERIMENTAL
Intervention: Verum Transcranial Pulse Stimulation (TPS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham Transcranial Pulse Stimulation (TPS)
Number of subjects: 34
Study: 34064370

Group type: EXPERIMENTAL
Intervention: Unilateral accentuated eccentric loading (AEL) in the leg press exercise of the dominant leg, performed twice a week for 10 weeks.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group without training.
Number of subjects: 69
Study: 32616238

Group type: EXPERIMENTAL
Intervention: Basal diet + 2% MOS meal
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Basal diet + 4% MOS meal
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control (CON), basal diet + 0% MOS meal
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: MOS diets (2% and 4%)
Number of subjects: 225
Study: 34848566

Group type: EXPERIMENTAL
Intervention: 1 g intravenous tranexamic acid over 10 min, followed by 1 g intravenous tranexamic acid over 8 hours
Number of subjects: 180

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 180
Study: 35507907

Group type: EXPERIMENTAL
Intervention: IPS Empress (n=20 teeth)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filtek Z250 (n=20 teeth)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IPS Empress
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filtek Z250
Number of subjects: 30
Study: 35877105

Group type: EXPERIMENTAL
Intervention: Intraventricular alteplase
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Stereotactic thrombolysis of hematoma
Number of subjects: 715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 715

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Resolution of ICH by day 30
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Resolution of IVH by day 30
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure less than 60 mm Hg
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Prolonged mechanical ventilation
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Need for intracranial pressure monitoring
Number of subjects: 715
Study: 35010653

Group type: EXPERIMENTAL
Intervention: Morning intake of creatine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Evening intake of creatine
Number of subjects: 14
Study: 32388650

Group type: EXPERIMENTAL
Intervention: Optimal PEEP (median=10, range: 8-14 cmH2O)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard PEEP (6 cmH2O)
Number of subjects: 39
Study: 32162533

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with BCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG therapy
Number of subjects: 0
Study: 35970327

Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2 mg (n = 486)
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2–3 mg (n = 770)
Number of subjects: 1256
Study: 34106630

Group type: EXPERIMENTAL
Intervention: Abdominal massage (vibration and ring massage), once a day, 30 minutes per session, for 5 days, totaling 4 courses of treatment.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spleen-invigorating bolus, orally, twice a day, 1 pill in the morning and 1 pill in the evening, for 5 days, totaling 4 courses of treatment.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy group (no intervention).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Functional MRI (Rs-fMRI) to observe BOLD signals in the brain, and MRS technology to observe GABA and 5-HT levels in the hypothalamus.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum analysis for CRH, ACTH, COR, GABA, NE, PGE2, and 5-HT levels.
Number of subjects: 60
Study: 32839976

Group type: EXPERIMENTAL
Intervention: 4-Hz neurostimulation of the itching area through matrix electrodes (EG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placement of matrix electrodes without neurostimulation (CG)
Number of subjects: 29
Study: 35038022

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 24 weeks (3 sessions/week)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Endurance Training (MIT) for 24 weeks (3 sessions/week)
Number of subjects: 27
Study: 33262252

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - loading dose 1 g over 10 min, then 1 g infusion over 8 hours
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Post-randomisation scan status
Number of subjects: 1767
Study: 34127294

Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study: 33833190

Group type: EXPERIMENTAL
Intervention: ActiGraph HRV protocol
Number of subjects: 64
Study: 36281683

Group type: EXPERIMENTAL
Intervention: Hydromethylthionine mesylate 16 mg/day
Number of subjects: 545

Group type: COMPARATOR
Intervention: Hydromethylthionine mesylate 8 mg/day
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study: 34275972

Group type: EXPERIMENTAL
Intervention: Diabetes codes alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diabetes codes and/or prescriptions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both diabetes codes and prescriptions
Number of subjects: 72
Study: 32556324

Group type: EXPERIMENTAL
Intervention: Dry cupping therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham cupping
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (no treatment)
Number of subjects: 32
Study: 35347643

Group type: EXPERIMENTAL
Intervention: Telephone Motivational Interviewing (TMI)
Number of subjects: 232
Study: 33223374

Group type: EXPERIMENTAL
Intervention: Invisalign treatment for Class II malocclusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Invisalign treatment for Class I malocclusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Invisalign treatment
Number of subjects: 40
Study: 33027748

Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35797790

Group type: EXPERIMENTAL
Intervention: New 'one-stop-shop' scan protocol combining brain CTP and head-and-neck CTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional scan protocol with separate brain CTP and head-and-neck CT examination
Number of subjects: 60
Study: 32371731

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine-alcohol solution
Number of subjects: 128

Group type: COMPARATOR
Intervention: 10% povidone-iodine solution
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 128
Study: 34265814

Group type: EXPERIMENTAL
Intervention: Self-selected (SS) cadence
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 60 PU·min ‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increasing cadence
Number of subjects: 44